BRIGHT Not So Clear on Lymphoma ChoiceBRIGHT Not So Clear on Lymphoma Choice

The BRIGHT study presented at ASH 2012 showed R-bendamustine to be noninferior to R-CHOP, but what role each regimen plays in lymphoma management is still unclear, says Dr. Bruce Cheson. Medscape Oncology

Source: Medscape Today Headlines - February 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news